Skip to main content
I

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Filings indexed 1,114 across all filing types
Latest filing 2025-02-25 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Oesophageal Cancer Collaboration and Funding Agreement 3 pages 245.7KB
Regulatory Filings
2025-02-25 English
Activities Report and Appendix 4C 9 pages 320.3KB
Regulatory Filings
2025-01-30 English
Application for quotation of securities - IVX 6 pages 18.4KB
Regulatory Filings
2025-01-22 English
Section 708A Cleansing Statement 2 pages 202.3KB
Regulatory Filings
2025-01-22 English
Notification regarding unquoted securities - IVX 7 pages 21.3KB
Regulatory Filings
2025-01-13 English
Application for quotation of securities - IVX 6 pages 18.4KB
Regulatory Filings
2025-01-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.